Yingtao Lin

Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China

Jingxuan Wei, Kai Xu, Yingtao Lin et al. · International Journal of Clinical Pharmacy · 2024 · 15 citations

Medicine, Oncology, Pharmacology +15

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Yingtao Lin, Ying Chen, Tianxiu Liu et al. · Cancer Management and Research · 2021 · 13 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer

Yingtao Lin, Chang Wang, Xiaoyan He et al. · Frontiers in Immunology · 2024 · 12 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China

Yingtao Lin, Tian-xiu Liu, Jian Chen et al. · Frontiers in Public Health · 2022 · 11 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis

Kai Xu, Man Yu, Qingli Sun et al. · Annals of Medicine · 2025 · 11 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17